Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
GSK and IQVIA have launched Vaccine Track, a new platform to enhance data transparency regarding adult vaccinations in the US. This resource aims to address the decline in adult immunization rates, particularly among minority populations, which saw an 18% drop in overall claims for recommended vaccinations from 2019 to 2021. The platform provides quarterly updates and diverse trend analyses, supporting public health efforts to improve vaccination rates post-pandemic. The initiative emphasizes the importance of vaccination data and could significantly impact public health policy.
IQVIA reported second-quarter 2022 revenue of $3,541 million, a 3.0% increase compared to the previous year, and 7.1% at constant currency. GAAP net income rose by 46.3% to $256 million, with diluted EPS increasing 48.9% to $1.34. Adjusted EBITDA reached $800 million, up 10.8% year-over-year. The R&D Solutions backlog grew 7.1% to $25.6 billion. For full-year guidance, revenue is now expected between $14,400 million and $14,550 million, reflecting 3.8% to 4.9% growth on a reported basis.
IQVIA Holdings Inc. (NYSE:IQV) has announced the upcoming release of its second-quarter 2022 financial results, scheduled for July 21, 2022, before the market opens. A conference call and webcast will follow at 9:00 a.m. Eastern Time that same day. The earnings release and detailed financial information will be available on the IQVIA Investor Relations website. A replay of the webcast will be accessible two hours after the event concludes, further enhancing investor engagement.
IQVIA announced the appointment of Dr. Christina Mack as chief scientific officer for its Real World Solutions business, effective July 7, 2022. She succeeds Dr. Nancy Dreyer, who is retiring after nearly two decades with the company. Dr. Mack has extensive experience in real-world evidence, improving patient care. Prior to this role, she was vice president of Epidemiology and Clinical Evidence. Her strong educational background includes degrees from the University of Notre Dame and the University of North Carolina at Chapel Hill.
In 2021, oncology trial starts soared by 56% since 2016, with a record 30 novel active substances launched globally. Despite this progress, oncologists face 20-29% lower caseloads than pre-COVID-19, with over 30 million cancer screenings disrupted, risking timely diagnoses for more than 58,000 patients. Global oncology spending is projected to exceed $300 billion by 2026, while treated patients have increased by an average of 4% annually. The surge in R&D signifies a promising future for cancer treatments, although challenges from the pandemic linger.
IQVIA Holdings Inc. (NYSE:IQV) will have CFO Ron Bruehlman speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022, at 11:30 a.m. ET. A live audio webcast of the presentation will be accessible on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research services for life sciences, operating in over 100 countries with approximately 82,000 employees. The company emphasizes patient privacy and utilizes various technologies to enhance healthcare outcomes.
IQVIA Holdings Inc. reported strong first-quarter 2022 results with revenue reaching $3,568 million, a 4.7% year-over-year increase. GAAP net income surged 53.3% to $325 million, while GAAP diluted EPS rose 54.1% to $1.68. Adjusted EBITDA was $812 million, up 9.1%. The record R&D solutions bookings exceeded $1.9 billion, with a backlog over $25 billion. Full-year revenue guidance has been updated to $14,450 million to $14,750 million, reflecting a 4.2% to 6.3% reported growth. Despite macro challenges, adjustments to EBITDA and EPS guidance reaffirm expected growth.
In 2021, spending on medicines in the U.S. reached $407 billion, a 12% increase from 2020, driven largely by COVID-19 vaccines and therapeutics. Prescription drug use hit a record 194 billion daily doses, with overall drug spending expected to return to pre-pandemic growth by 2023. However, patient out-of-pocket costs rose $4 billion in 2021, reflecting ongoing economic pressures. The report indicates a shift towards biosimilars affecting branded drug sales and forecasts a 2.1% compound annual growth in medicine spending through 2026.
IQVIA Holdings Inc. will announce its first-quarter 2022 financial results on April 27, 2022, before the market opens. The management will host a conference call and webcast at 9:00 a.m. Eastern Time. Interested participants must register in advance to join the call and will receive details via email. A replay of the webcast will be accessible two hours post-event. IQVIA is a leading provider of analytics and clinical research services in the life sciences, operating in over 100 countries with about 79,000 employees.
